{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-24-000046","form_type":"8-K/A","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.460412+00:00","generated_at":"2026-06-02T01:10:17.233104+00:00","sec_items":["7.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Barinthus Bio Q1 net loss $15.5M; VTP-200 misses stat sig; VTP-1000 IND cleared; CMO appointed","bullets":["Net loss was $15.5M ($0.40/share), compared to $18.2M ($0.48) in Q1 2023; revenue nil.","Cash position $130.0M as of Mar 31, 2024; cash runway into Q4 2025.","VTP-200 Phase 1b/2 APOLLO met safety but no stat sig improvement in hrHPV or lesion clearance vs placebo.","VTP-1000 IND cleared for Phase 1 celiac trial; first patient dosing expected Q3 2024.","Appointed Dr. Leon Hooftman as CMO effective June 3, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-24-000046","json":"https://secwatch.observer/filing/0001828185-24-000046.json","markdown":"https://secwatch.observer/filing/0001828185-24-000046.md","text":"https://secwatch.observer/filing/0001828185-24-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000046/0001828185-24-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000046/brns-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:10:17.233104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"579f6e233c95971ccc49e0d8e0efd72097917895","claim":"Barinthus Biotherapeutics plc. reported first quarter of 2024 results: revenue nil.","evidence_excerpt":"On May 13, 2024, the Company announced its financial results for the first quarter of 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000046/0001828185-24-000046-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"nil"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}